Administration

行政

• 批准号: 10624797
• 负责人: Ruth Margrit Ruprecht
• 金额: $ 25.55万
• 依托单位: UNIVERSITY OF LOUISIANA AT LAFAYETTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10624797
• 关键词: Achievement; Acquired Immunodeficiency Syndrome; Address; Area; Biomedical Research; Biotechnology; Budgets; Businesses; Cold Chains; Collaborations; Communication; Country; Equity; Europe; European; Experimental Designs; Goals; HIV vaccine; HIV-1; Image; Immunology; Individual; Infectious Agent; Institution; Intellectual Property; Lead; Louisiana; Macaca mulatta; Manuscripts; Medicine; Modeling; Monitor; Mucous Membrane; National Institute of Allergy and Infectious Disease; Needles; Oral; Positron-Emission Tomography; Primates; Protocols documentation; Publications; Radionuclide Imaging; Reagent; Reporting; Research; Research Institute; Research Personnel; Resources; Sampling; Science; Scientist; Site Visit; Solid; Switzerland; Technology; Texas; Training; Travel; United States National Institutes of Health; Universities; Viral Pathogenesis; Virginia; Virosome Vaccines; Virosomes; Visit; Washington; capsule; data dissemination; design; dosage; ileum; innovation; manufacturing capabilities; manufacturing process; material transfer agreement; meetings; nonhuman primate; novel vaccines; payment; prevent; programs; simian human immunodeficiency virus; skills; translational goal; vaccine delivery; vaccine formulation; vaccine immunogenicity; vaccine platform; whole body imaging

The overall objective of administrative Core A is to provide this multi-PI, multi-institutional U19 IPCAVD Project the opportunity to interact synergistically by facilitating the communication among the Project Leaders and all participating scientists. Core A will also serve as liaison between Research Administration at the contact institution, the Texas Biomedical Research Institute (TxBiomed), all the affiliated institutions both in the US and in Europe, and NIAD representatives. The network of partnering scientists includes researchers in Texas, Louisiana, Georgia and several countries in Europe; the major partner is Mymetics in Switzerland. The innovative biotech company has developed gp41-based virosomes into to a novel vaccine platform that is cold-chain independent and can be administered mucosally without needles. The Specific Aims of Core A are to: 1. Provide administrative support and facilitate the collaboration among Projects 1 and 2 and the various subcontract/subaward leaders and partners. This will include the exchange of information, reagents, and material transfer agreements. 2. Set priorities, monitor progress and jointly make go/no-go decisions. This will be achieved with input from the External Scientific Advisory Board (ESAB) and the NIAID IPCAVD Program Officer. 3. Assist in the design of experiments in rhesus macaques (RMs), protocol design and submission, and exchange of samples between the New Iberia Research Center (NIRC), where the primate studies will be conducted, and TxBiomed. 4. Provide statistical support for all IPCAVD scientists through the participation of Dr. Sarah Ratcliffe through a subaward with the University of Virginia (UVA). 5. Provide financial oversight and assure prompt payment of bills as well as the timely achievement of the experimental goals within budget limits. 6. Organize the yearly NIH Site Visit and the External Scientific Advisory Board (ESAB) meeting in the Washington, D.C. area, as well as individual visits between Drs. Ruprecht, Villinger, Santangelo and Fleury. 7. Address intellectual property (IP) issues fairly, timely, and equitably. 8. Facilitate the submission of reports, dissemination of data at meetings, and publication of manuscripts. To meet the goals of this translational, highly interactive U19 Research Program, the Core A Leader/Contact PI depends on the trained professionals with excellent organization skills as well as basic understanding of science and medicine to make this U19 network of scientists successful.

行政核心A的总体目标是提供这个多PI、多机构的U19 IPCAVD项目 通过促进项目负责人和所有人员之间的沟通，实现协同互动的机会 参与其中的科学家。核心A还将在联系人处担任研究管理部门之间的联络人 机构，德克萨斯生物医学研究所(TxBimed)，所有附属机构在美国和 在欧洲，以及NIAD代表。合作科学家网络包括德克萨斯州的研究人员， 路易斯安那州、佐治亚州和欧洲几个国家；主要合作伙伴是瑞士的Mymetics。创新的 一家生物技术公司已经将基于gp41的病毒体开发成一种新的疫苗平台，即冷链 独立的，无需针头即可粘膜给药。 核心A的具体目标是： 1.提供行政支持，促进项目1、2和各项目之间的协作 分包/分包领导和合作伙伴。这将包括交换信息、试剂和 材料转让协议。 2.设定轻重缓急，监督进展，共同做出通过/不通过决定。这将通过输入来实现 来自外部科学咨询委员会(ESAB)和NIAID IPCAVD项目官员。 3.协助设计恒河猴(RMS)实验、方案设计和提交，以及 在新伊比利亚研究中心(NIRC)之间交换样本，灵长类研究将在那里 被引导，并产生TxBied。 4.通过Sarah Ratcliffe博士的参与，为所有IPCAVD科学家提供统计支持 通过弗吉尼亚大学(UVA)的子奖。 5.提供财务监督，确保及时支付账单，并及时实现 在预算范围内实现试验性目标。 6.组织国家卫生研究院年度实地考察和外部科学咨询委员会(ESAB)会议 华盛顿特区地区，以及鲁普雷希特博士、维林格博士、桑坦格洛博士和 弗洛里。 7.公平、及时、公正地解决知识产权问题。 8.便利提交报告、在会议上传播数据和出版手稿。 为了实现这一翻译、高度互动的U19研究计划的目标，核心领导/联系人PI 依靠训练有素的专业人员，具有出色的组织能力和对科学的基本理解 和药物，使这个U19科学家网络取得成功。